A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan's Approval Of Dupixent For Bullous Pemphigoid [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults with moderate to severe bullous pemphigoid, expanding the drug's reach in a rare skin disease. See our latest analysis for Regeneron Pharmaceuticals. The Dupixent approval in Japan has arrived while Regeneron's 1 day share price return of 1.57% and 7 day share price return of 1.73% contrast with a 30 day share price decline of 4.14%, and a 1 year total shareholder return of 18.79%, alongside a weaker 3 year total shareholder return. If this kind of specialty healthcare story interests you, it could be a good moment to see what else is moving with 34 healthcare AI stocks With REGN trading at US$749.29 and sitting at a 16% discount to the average analyst price target, and a reported 58% intrinsic discount, the key question is whether this represents genuine value or if the market already reflects expectations for future growth. Most Popular Narrative: 14.
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- NTLA Stock Rises 20% in 3 Months: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What's Next [Yahoo! Finance]Yahoo! Finance
- Regeneron and Telix Announce Strategic Radiopharma CollaborationGlobeNewswire
- Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)GlobeNewswire
- Telix and Regeneron Announce Strategic Radiopharma CollaborationPR Newswire
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 4/8/26 - Form 8-K
- 4/3/26 - Form 4
- 3/27/26 - Form SCHEDULE
- REGN's page on the SEC website